{"id":"NCT00662038","sponsor":"Genentech, Inc.","briefTitle":"Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)","officialTitle":"An Open-Label Extension Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-08","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2008-04-21","resultsPosted":"2017-03-29","lastUpdate":"2017-03-29"},"enrollment":1058,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Pulmonary Fibrosis"],"interventions":[{"type":"DRUG","name":"pirfenidone","otherNames":[]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"}],"summary":"This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone. The purpose of this study is to obtain additional safety data for pirfenidone 2403 mg/day in patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events","timeFrame":"7.5 years","effectByArm":[{"arm":"Pirfenidone","deltaMin":98,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["37391667","30950636","28898890","26835133"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":571,"n":1058},"commonTop":["Cough","Dyspnoea","Nausea","Upper respiratory tract infection","Bronchitis"]}}